CSIMarket
 
Kempharm Inc  (KMPH)
Other Ticker:  
 
 


Failed to reach profitability despite the surge in Revenues, the company all along the July to September 30 2022 time-frame

Kempharm Inc delivered third quarter of 2022 operating deficit of $-6.626 millions

Published 2022-11-12T19:26:49+00:00
Goran Soko / CSIMarket.com Contributer

pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_CommonsKempharm Inc Losses have extended at $-0.19 per share in the July to September 30 2022 time-frame, although its Revenues surged by 46.26 % to $2.87 millions from the same financial reporting period a year before.

In the preceding financial reporting period Major Pharmaceutical Preparations company realized Revenue of $1.30 millions and $-0.70 per share.


For the third quarter of 2022 Kempharm Inc realized net loss of $-6.616 million, larger than $-1.759 million a year ago.


Kempharm Inc is expected to report next financial earnings on March 29, 2023.


    Recently Reported Results